Selecta Biosciences Appoints CMO
This article was originally published in Scrip
Selecta Biosciences Inc., which is developing a novel class of targeted antigen-specific immune therapies using Synthetic Vaccine Particles (SVP), has appointed Dr Earl Sands as chief medical officer. Prior to joining Selecta, Sands was most recently chief medical officer of Targacept.
Register for our free email digests: